Eczematous reactions to psoriasis biologics treated with dupilumab: A case series

Psoriasis is characterized by a T helper (Th)1 and Th17 immune response and a unique cytokine profile, including elevated interleukin (IL)-17 and IL-23.1 Biologic therapy for psoriasis targets the imbalance of cytokines characteristic of the disease and has revolutionized disease management. However, recent reports have described eczematous eruptions that occur as adverse reactions to biologic therapy for psoriasis and often require discontinuation of the biologic.2 Here, we report of 3 patients, who developed eczematous reactions while on a biologic targeting Th1 or Th17 cytokines. We successfully treated the reactions with the addition of dupilumab to the existing biologic regimen with no adverse events.